Mitchell B. Diccianni

2.1k citations

40 papers · 1.5k indexed · h-index 24

Neurology top 2%
- Neuroblastoma Research and Treatments 18
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 12
Oncology top 10%
- Cancer-related Molecular Pathways 8
- Lung Cancer Research Studies 3
Molecular Biology top 10%
- Epigenetics and DNA Methylation 4
- Cancer therapeutics and mechanisms 4
- RNA modifications and cancer 3
Hematology top 10%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 5

Co-authors: Alice L. Yu Ayse Batova Wendy B. London John Yu Jeanette Pullen Paul M. Sondel Arlene Naranjo John M. Maris
Cited by: Neurology Cancer Research Oncology
Journals: Journal of Biological Chemistry (1 paper)Journal of Clinical Oncology (3 papers)Blood (3 papers)
Partner nations: United States Taiwan Japan

In The Last Decade

Mitchell B. Diccianni

40 papers receiving 1.5k citations

Peers

Countries citing papers authored by Mitchell B. Diccianni

Since Specialization

Citations

This map shows the geographic impact of Mitchell B. Diccianni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell B. Diccianni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell B. Diccianni more than expected).

Fields of papers citing papers by Mitchell B. Diccianni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell B. Diccianni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell B. Diccianni. The network helps show where Mitchell B. Diccianni may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mitchell B. Diccianni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mitchell B. Diccianni Line = papers co-authored together Mitchell B. Diccianni links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group European Journal of Cancer ·Pooja Hingorani,Mark Krailo,Allen Buxton,Paul R. Hutson,Paul M. Sondel,Mitchell B. Diccianni,Alice L. Yu,Carol D. Morris,Richard B. Womer,Brian D. Crompton,R. Lor Randall,Lisa A. Teot,Steven G. DuBois,Katherine A. Janeway,Richard Görlick,Michael S. Isakoff	2022	23
2	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 Clinical Cancer Research ·Alice L. Yu,Andrew L. Gilman,M. Fevzi Özkaynak,Arlene Naranjo,Mitchell B. Diccianni,Jacek Gan,Jacquelyn A. Hank,Ayse Batova,Wendy B. London,Sheena C. Tenney,Malcolm A. Smith,Barry L. Shulkin,Marguerite T. Parisi,Katherine K. Matthay,Susan L. Cohn,John M. Maris,Rochelle Bagatell,Julie R. Park,Paul M. Sondel	2021	132
3	Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO PLoS ONE ·Mitchell B. Diccianni,Katarzyna Kempińska,Jon A. Gangoti,Alice L. Yu,Linda S. Sorkin	2020	5
4	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 Frontiers in Immunology ·M. Fevzi Özkaynak,Andrew L. Gilman,Wendy B. London,Arlene Naranjo,Mitchell B. Diccianni,Sheena C. Tenney,Malcolm A. Smith,Karen Messer,Robert C. Seeger,C. Patrick Reynolds,L. Mary Smith,Barry L. Shulkin,Marguerite T. Parisi,John M. Maris,Julie R. Park,Paul M. Sondel,Alice L. Yu	2018	62
5	Comparison of bead array and glass nanoreactor multi-analyte platforms for the evaluation of CNS and peripheral inflammatory markers during HIV infection Journal of Immunological Methods ·Albert M. Anderson,Minh Ly Nguyen,Michael Potter,Debra Rosario,Katarzyna Kempińska,Ronald J. Ellis,Mitchell B. Diccianni,Scott Letendre	2018	2
6	Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial The Lancet Oncology ·Rajen Mody,Arlene Naranjo,Collin Van Ryn,Alice L. Yu,Wendy B. London,Barry L. Shulkin,Marguerite T. Parisi,Sabah-E-Noor Servaes,Mitchell B. Diccianni,Paul M. Sondel,Julia Glade Bender,John M. Maris,Julie R. Park,Rochelle Bagatell	2017	182
7	High Expression of CAI2 , a 9p21 -Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma Cancer Research ·Lisa M. Barnhill,Richard T. Williams,Olga Cohen,Young-Jin Kim,Ayse Batova,Jenna A. Mielke,Karen Messer,Minya Pu,Lei Bao,Alice L. Yu,Mitchell B. Diccianni	2014	39
8	Chimeras of p14ARF and p16: Functional Hybrids with the Ability to Arrest Growth PLoS ONE ·R. T. Williams,Lisa M. Barnhill,Huan-Hsien Kuo,Wender Lin,Ayse Batova,Alice L. Yu,Mitchell B. Diccianni	2014	10
9	Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue Free Radical Biology and Medicine ·Michael J. Kelner,Mitchell B. Diccianni,Alice L. Yu,Mary Rutherford,Leita A. Estes,Ralf Morgenstern	2014	12
10	Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy Journal of Experimental & Clinical Cancer Research ·R. T. Williams,Alice L. Yu,Mitchell B. Diccianni,Emmanuel A. Theodorakis,Ayse Batova	2013	34
11	microRNA Signature and Expression of Dicer and Drosha Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma Cancer Research ·Ruey‐Jen Lin,You-Chin Lin,Jeremy Chen,Huan-Hsien Kuo,Yuan-Yan Chen,Mitchell B. Diccianni,Wendy B. London,Chih‐Hao Chang,Alice L. Yu	2010	146
12	MPDA: Microarray pooled DNA analyzer BMC Bioinformatics ·Hsin‐Chou Yang,Mei-Chu Huang,Ling‐Hui Li,Chien‐Hsing Lin,Alice L. Yu,Mitchell B. Diccianni,Jer‐Yuarn Wu,Yuan-Tsong Chen,Cathy S.J. Fann	2008	9
13	Frequent deregulation ofp16 and thep16/G1 cell cycle-regulatory pathway in neuroblastoma International Journal of Cancer ·Mitchell B. Diccianni,Motoko Omura‐Minamisawa,Ayse Batova,Thanh Van Le,L J Bridgeman,Alice L. Yu	1999	33
14	Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions Leukemia Research ·Mitchell B. Diccianni,Ayse Batova,John Yu,Thai Vu,Jeanette Pullen,Michael D. Amylon,Brad H. Pollock,Alice L. Yu	1997	33
15	Activation of Glutathione Transferase P Gene by Lead Requires Glutathione Transferase P Enhancer I Journal of Biological Chemistry ·Toshiya Suzuki,Shigeru Morimura,Mitchell B. Diccianni,R Yamada,Shinichi Hochi,Masumi Hirabayashi,Atsushi Yuki,Kimie Nomura,Tomoyuki Kitagawa,Masayoshi Imagawa,Masami Muramatsu	1996	37
16	The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance Cancer Letters ·Mitchell B. Diccianni,Lan S. Chau,Ayse Batova,Thai Q. Vu,Alice L. Yu	1996	22
17	Heparin prevents the binding of phospholipase A2 to phospholipid micelles: importance of the amino-terminus Biochemistry ·Mitchell B. Diccianni,M Lilly-Stauderman,L. McLean,A. Balasubramaniam,Judith A.K. Harmony	1991	25
18	SF-B that binds to a negative element in glutathione transferase P gene is similar or identical to trans-activator Biochemical and Biophysical Research Communications ·Masayoshi Imagawa,Shigehiro Osada,Yumi Koyama,Toshiya Suzuki,P. C. Hirom,Mitchell B. Diccianni,Shigeru Morimura,Masami Muramatsu	1991	34
19	Porcine pancreatic phospholipase A2 isoforms: differential regulation by heparin Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Mitchell B. Diccianni,Larry R. McLean,William D. Stuart,Meenakshi J. Mistry,Cleris M. Gil,Judith A.K. Harmony	1991	6
20	Inhibition of phospholipase A2 by heparin Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Mitchell B. Diccianni,Meenakshi J. Mistry,Katherine Hug,Judith A.K. Harmony	1990	24

About Mitchell B. Diccianni

Mitchell B. Diccianni is a scholar working on Neurology, Cancer Research and Oncology, having authored 40 papers that have together received 1.5k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (18 papers), Cancer, Hypoxia, and Metabolism (12 papers), Cancer-related Molecular Pathways (8 papers), Acute Lymphoblastic Leukemia research (5 papers), Epigenetics and DNA Methylation (4 papers), Cancer therapeutics and mechanisms (4 papers), Lung Cancer Research Studies (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Neurology (615 citations), Cancer Research (407 citations) and Oncology (435 citations). Mitchell B. Diccianni has collaborated with scholars based in United States, Taiwan and Japan. Frequent co-authors include Alice L. Yu, Ayse Batova, Wendy B. London, John Yu, Jeanette Pullen, Paul M. Sondel, Arlene Naranjo, John M. Maris, Marguerite T. Parisi and Barry L. Shulkin. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact